{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:24:18Z","timestamp":1776756258180,"version":"3.51.2"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.euroneuro.2016.07.010","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T21:40:41Z","timestamp":1470260441000},"page":"1353-1365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome"],"prefix":"10.1016","volume":"26","author":[{"given":"Jorge","family":"Zimbron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golam M.","family":"Khandaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Toschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Fernandez-Egea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2016.07.010_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0269881108089816","article-title":"Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial","volume":"23","author":"Afshar","year":"2009","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4088\/JCP.09m05402yel","article-title":"Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study","volume":"72","author":"Bai","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3371\/CSRP.5.1.3","article-title":"Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine","volume":"5","author":"Ball","year":"2011","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"Suppl 23","key":"10.1016\/j.euroneuro.2016.07.010_bib5","first-page":"45","article-title":"Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle","volume":"62","author":"Basile","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib6","first-page":"270","article-title":"Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial","volume":"14","author":"Behdani","year":"2011","journal-title":"Arch. Iran. Med."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/NDT.S40554","article-title":"A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice","volume":"9","author":"Bod\u00e9n","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4088\/JCP.v63n0412","article-title":"Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment","volume":"63","author":"Borovicka","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/schbul\/16.4.551","article-title":"At issue: defining treatment refractoriness in schizophrenia","volume":"16","author":"Brenner","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","article-title":"Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study","volume":"113","author":"Carrizo","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib11","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.4088\/JCP.12m08186","article-title":"Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study","volume":"74","author":"Chen","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib12","unstructured":"Cochrane Informatics & Knowledge Management Department, 2015. RevMan."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1461145707007547","article-title":"Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis","volume":"10","author":"De Luca","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib15","unstructured":"European Medicines Agency, 2010. Questions and answers on the suspension of medicines containing sibutramine."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/acps.12009","article-title":"Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia","volume":"127","author":"Fan","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib17","series-title":"Interventions to reduce weight gain in schizophrenia, in: Cochrane Database of Systematic Reviews","author":"Faulkner","year":"2007"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1034\/j.1600-0447.2003.00218.x","article-title":"Schizophrenia and weight management: a systematic review of interventions to control weight","volume":"108","author":"Faulkner","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/157340012798994867","article-title":"Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers","volume":"8","author":"Fiedorowicz","year":"2012","journal-title":"Curr. Psychiatry Rev."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib21","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.08m04683","article-title":"Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial","volume":"70","author":"Freudenreich","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/jcp.0b013e318161318f","article-title":"A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia","volume":"28","author":"Friedman","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4088\/JCP.v63n1010","article-title":"Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database","volume":"63","author":"Gianfrancesco","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4103\/1735-1995.158262","article-title":"Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder","volume":"20","author":"Hebrani","year":"2015","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","article-title":"A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain","volume":"162","author":"Henderson","year":"2005","journal-title":"Am. J Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0447.2006.00855.x","article-title":"A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain","volume":"115","author":"Henderson","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0447.2008.01325.x","article-title":"A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia","volume":"119","author":"Henderson","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2011.04.009","article-title":"Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia","volume":"130","author":"Henderson","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00041444-200209000-00009","article-title":"Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment","volume":"12","author":"Hong","year":"2002","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.v69n0503","article-title":"Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial","volume":"69","author":"Joffe","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib32","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1056\/NEJM200012213432501","article-title":"Phenylpropanolamine and the risk of hemorrhagic stroke","volume":"343","author":"Kernan","year":"2000","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.wnf.0000172994.56028.c3","article-title":"Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain","volume":"28","author":"Ko","year":"2005","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications","volume":"17","author":"Lett","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1345\/aph.19412","article-title":"Orlistat--a novel weight loss therapy","volume":"35","author":"Lucas","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib37","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/npp.2010.21","article-title":"Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis","volume":"35","author":"Maayan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib301","unstructured":"Meltzer, H.Y., 1994. An Overview of the Mechanism of Action of Clozapine. Journal of Clinical Psychiatry 55, no. Suppl B, 47\u201352"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib38","first-page":"309","article-title":"Pharmacogenetics of antipsychotic-induced weight gain","volume":"49","author":"M\u00fcller","year":"2004","journal-title":"Pharmacol. Res., Trends Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0269881110372548","article-title":"Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study","volume":"25","author":"Muscatello","year":"2011","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib40","unstructured":"NICE, 2014. CG178 Psychosis and schizophrenia in adults: NICE guideline [WWW Document]. NICE. URL \u3008http:\/\/www.nice.org.uk\/\u3009 (accessed 6.12.14)."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib41","unstructured":"Novartis, 2002. Clozaril. Summary of product characteristics for the FDA."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib42","first-page":"CD004094","article-title":"Long-term pharmacotherapy for obesity and overweight","author":"Padwal","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.9758\/cpn.2012.10.2.71","article-title":"Pharmacogenetic aspects of antipsychotic drug-induced weight gain - a critical review","volume":"10","author":"Reynolds","year":"2012","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib45","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/00001756-199705260-00040","article-title":"Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor","volume":"8","author":"Rietschel","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib47","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib48","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2217\/pgs.10.123","article-title":"Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis","volume":"11","author":"Sicard","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1176\/ajp.155.5.693","article-title":"Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder","volume":"155","author":"Spencer","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/0253-7176.43131","article-title":"Study of effects of modafinil add-on therapy on excessive day time drowsiness and weight gain in patients on atypical antipsychotics","volume":"30","author":"Sudhakar","year":"2008","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4088\/JCP.09m05283yel","article-title":"Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial","volume":"72","author":"Tchoukhine","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00041444-200512000-00011","article-title":"Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs","volume":"15","author":"Theisen","year":"2005","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib53","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1192\/bjp.185.4.334","article-title":"Patterns of hospital admission for adult psychiatric illness in England: analysis of Hospital Episode Statistics data","volume":"185","author":"Thompson","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-011-2211-x","article-title":"Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication","volume":"216","author":"Vehof","year":"2011","journal-title":"Psychopharmacology (Berl. )"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2012.02.021","article-title":"Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study","volume":"138","author":"Wang","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib56","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-015-1807-1","article-title":"Treatment of clozapine-associated weight gain: a systematic review","volume":"71","author":"Whitney","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2016.07.010_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms","volume":"58","author":"Wiernsperger","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib58","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","article-title":"Novel antipsychotics: comparison of weight gain liabilities","volume":"60","author":"Wirshing","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.010_bib59","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ps.2007.58.4.544","article-title":"Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program","volume":"58","author":"Wu","year":"2007","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/978-1-4613-0381-7_89","article-title":"The effects of peripheral serotonin2 receptor agonist on food intake of rats","volume":"398","author":"Yamada","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"issue":"Supplement 1","key":"10.1016\/j.euroneuro.2016.07.010_bib61","first-page":"S318","article-title":"Pharmacogenetics of weight gain and obesity following clozapine treatment","volume":"22","author":"Yevtushenko","year":"2007","journal-title":"Eur. Psychiatry, 15th AEP Congr. Abstr. book 15th AEP Congr."},{"key":"10.1016\/j.euroneuro.2016.07.010_bib62","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"New Engl. J. Med."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16301201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16301201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:36:26Z","timestamp":1692452186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16301201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0924977X16301201"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.07.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}